The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia

Expert Opinion on Drug Discovery
Etienne PaubelleXavier Thomas

Abstract

Acute myeloid leukemia (AML) represents a disease with a very poor outcome and remains an area of significant unmet need necessitating novel therapeutic strategies. Among novel therapeutic agents, vosaroxin is a first-in-class anticancer quinolone derivative that targets topoisomerase II and induces site-selective double-strand breaks in DNA, leading to tumor cell apoptosis. Areas covered: Herein, the authors provide a comprehensive review of the preclinical development of vosaroxin. This includes coverage of vosaroxin's mechanism of action in addition to its pharmacology and of the main studies reported over the past few years with vosaroxin when used to treat adult AML. Expert opinion: Given that vosaroxin is associated with fewer potential side effects, it may be of benefit to elderly patients with relapsed/refractory AML and to those with additional comorbidities who have previously received an anthracycline and cytarabine combination. Furthermore, vosaroxin also was seen to be active in multidrug-resistant preclinical models. However, further studies have to be performed to better evaluate its place in the armamentarium against AML.

References

Mar 4, 2000·Progress in Nucleic Acid Research and Molecular Biology·J M Fortune, N Osheroff
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D C Hooper
Jun 4, 2002·Nature Reviews. Molecular Cell Biology·James C Wang
Oct 22, 2008·Cancer Chemotherapy and Pharmacology·Ute HochJeffrey A Silverman
Apr 21, 2009·Nature Reviews. Cancer·John L Nitiss
Apr 21, 2009·Nature Reviews. Cancer·John L Nitiss
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Mar 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ranjana H AdvaniDaniel C Adelman
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettDonald Milligan
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield

❮ Previous
Next ❯

Citations

Oct 30, 2019·Mini Reviews in Medicinal Chemistry·Xu HuDahong Li
Sep 26, 2020·Journal of Enzyme Inhibition and Medicinal Chemistry·Kamila BuzunAgnieszka Gornowicz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.